EUVIMEDEUVIMED entdecken
Multizentrische Studie

The utility of [18F]FDG PET in discriminating between local recurrence and inflammatory changes following SABR in primary lung cancer patients

Maria Fala iD, Eleni Josephides, Sweni Shah, Hemal Ariyaratne, Anant Patel, Gary J R Cook, Sugama Chicklore, Thomas Wagner

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07400-1 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Maria Fala und 7 weiteren Autor:innen. Beteiligte Einrichtung: Royal Free London NHS Foundation Trust, London, UK. Mariatfala@gmail.com. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Lung Neoplasms, Positron Emission Tomography Computed Tomography, Neoplasm Recurrence, Local. Die Arbeit nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Stereotactic ablative radiotherapy (SABR) is used in patients with early-stage primary lung cancer who are not fit for surgery or who refuse surgery. Post-treatment, patients are monitored with surveillance CT, with [18F]FDG PET-CT often used for further investigation if there is suspicion of recurrence on CT. This study investigated the utility of [18F]FDG PET-CT in detecting recurrence in patients with suspicious CT findings. METHODS: This is a dual-centre retrospective study of 754 consecutive patients who received SABR for lung lesions in our institutions between 2012 and 2023. Seventy-four FDG PET-CT scans from 65 patients, performed at a median of 585 days after SABR were included. SUVmax and subjective score of likelihood of recurrence were recorded. Follow-up imaging, biopsy and resection histology, where available, were used to ascertain the patients' outcome. RESULTS: Out of 74 included FDG PET-CT scans, there were 11 local recurrences and 63 non-recurrences by reference standard. The SUVmax of the lesion post-SABR was significantly higher in patients who had recurrent tumour (median 4.3, range 2.2-16.1) compared to those who did not (median 3.3, range 1.4-6.4) (p = 0.011). Subjective scores of likelihood of recurrence performed better than SUVmax readings alone with positive and negative predictive values of 0.45 and 0.96, respectively, which are significantly improved to 0.94 and 1.00 when only including tumours with baseline SUVmax > 5.0. CONCLUSION: FDG PET is useful in guiding management of patients with suspected recurrence after SABR, particularly in cases where the tumour is FDG avid pre-treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18Lung NeoplasmsPositron Emission Tomography Computed TomographyNeoplasm Recurrence, LocalRadiosurgeryHumansFemaleMaleAgedMiddle AgedRetrospective StudiesAged, 80 and overAdultInflammationDiagnosis, Differential

Stichwörter der Autor:innen

18F-FDG PET-CTLung cancerRecurrenceSABR

Substanzen

Fluorodeoxyglucose F18

Autor:innen und Institutionen

  • Royal Free London NHS Foundation Trust, London, UK. Mariatfala@gmail.com.
  • Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Royal Free London NHS Foundation Trust, London, UK.
  • East & North Hertfordshire NHS Trust, Stevenage, UK.
  • King's College London & Guy's and St. Thomas' PET Centre, St Thomas' Hospital, London, UK.
  • School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.

ORCID-Profile: Maria Fala

Zitieren

APA

Fala, M., Josephides, E., Shah, S., Ariyaratne, H., Patel, A., Cook, G. J. R., Chicklore, S., & Wagner, T. (2025). The utility of [18F]FDG PET in discriminating between local recurrence and inflammatory changes following SABR in primary lung cancer patients. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07400-1

Vancouver

Fala M, Josephides E, Shah S, Ariyaratne H, Patel A, Cook GJR, et al. The utility of [18F]FDG PET in discriminating between local recurrence and inflammatory changes following SABR in primary lung cancer patients. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07400-1

BibTeX
@article{Fala2025,
  author = {Fala, Maria and Josephides, Eleni and Shah, Sweni and Ariyaratne, Hemal and Patel, Anant and Cook, Gary J R and Chicklore, Sugama and Wagner, Thomas},
  title = {The utility of [18F]FDG PET in discriminating between local recurrence and inflammatory changes following SABR in primary lung cancer patients},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07400-1}
}
Kostenlos starten →